Ibex Wealth Advisors raised its position in shares of Pfizer (NYSE:PFE) by 23.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,156 shares of the biopharmaceutical company’s stock after purchasing an additional 7,928 shares during the quarter. Ibex Wealth Advisors’ holdings in Pfizer were worth $1,500,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. First Dallas Securities Inc. purchased a new position in shares of Pfizer in the fourth quarter worth $118,000. Americafirst Capital Management LLC purchased a new position in shares of Pfizer in the third quarter worth $127,000. Delphi Private Advisors LLC lifted its holdings in shares of Pfizer by 84.3% in the fourth quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,600 shares in the last quarter. Oak Point Wealth Management purchased a new position in shares of Pfizer in the fourth quarter worth $165,000. Finally, Cerebellum GP LLC purchased a new position in shares of Pfizer in the fourth quarter worth $166,000. 69.53% of the stock is currently owned by institutional investors and hedge funds.
Pfizer opened at $35.80 on Tuesday, Marketbeat.com reports. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.45. Pfizer has a twelve month low of $31.67 and a twelve month high of $39.43. The firm has a market cap of $212.16 billion, a price-to-earnings ratio of 13.51, a PEG ratio of 1.77 and a beta of 0.89.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.03. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The business had revenue of $12.91 billion for the quarter, compared to analysts’ expectations of $13.14 billion. During the same quarter in the previous year, the business posted $0.69 earnings per share. The business’s revenue was up 1.0% compared to the same quarter last year. analysts anticipate that Pfizer will post 2.95 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, May 11th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.80%. The ex-dividend date is Thursday, May 10th. Pfizer’s dividend payout ratio (DPR) is 51.32%.
PFE has been the topic of several research analyst reports. Morningstar set a $38.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. Credit Suisse Group reissued a “neutral” rating and issued a $39.00 target price on shares of Pfizer in a report on Friday. Barclays downgraded shares of Pfizer from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $41.00 to $38.00 in a report on Thursday, April 5th. UBS set a $42.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a report on Wednesday, January 24th. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $40.08.
In other Pfizer news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $37.19, for a total transaction of $353,676.90. Following the transaction, the insider now owns 36,959 shares in the company, valued at $1,374,505.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mikael Dolsten sold 13,986 shares of the business’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $35.85, for a total transaction of $501,398.10. Following the transaction, the insider now owns 120,884 shares in the company, valued at approximately $4,333,691.40. The disclosure for this sale can be found here. Insiders have sold 380,349 shares of company stock worth $13,829,340 in the last quarter. Company insiders own 0.06% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.